Crinetics Pharmaceuticals Inc
CRNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.98B
Close$
$-12.03
114.2% downside
Current Fair Value
114.2% downsideOvervalued by 114.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.98 Billion |
|---|---|
| Enterprise Value | $8.92 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.95 |
| Beta | 0.13 |
| Outstanding Shares | 105,560,000 |
Return
| Return on Equity | -42.08% |
|---|---|
| Return on Assets | -37.95% |
| Return on Invested Capital | -43.32% |
Valuation & Multiples
| P/E Ratio | -16.77 |
|---|---|
| PEG | -371.69 |
| Price to Sales | - |
| Price to Book Ratio | 7.68 |
| Enterprise Value to Revenue | 223.71 |
| Enterprise Value to EBIT | -16.58 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.23
Average shareholder expectationRevenue Estimate
$14.82 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$21.04 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 105.08% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.12%▼ 98.82% |
|---|---|
| Total Invested | $744.85M▼ 83.29% |
| Investors Holding | 100▼ 149.00% |
ESG Score
No data
About Crinetics Pharmaceuticals Inc
CEO: R. Scott Struthers